Base-edited hematopoietic stem and progenitor cells + ALEMTUZUMAB + Busulfan + FILGRASTIM + PALIFERMIN + PLERIXAFOR

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Base-edited hematopoietic stem and progenitor cells + ALEMTUZUMAB + Busulfan + FILGRASTIM + PALIFERMIN + PLERIXAFOR
Treatment and conditionWhere it standsTrials
Base-edited hematopoietic stem and progenitor cells + ALEMTUZUMAB + Busulfan + FILGRASTIM + PALIFERMIN + PLERIXAFOR for x-linked combined immunodeficiency diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1